Macquarie Group’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-200,717
| Closed | -$6.04M | – | 1353 |
|
|
2025
Q3 | $6.04M | Sell |
200,717
-34,380
| -15% | -$1.03M | 0.01% | 919 |
|
|
2025
Q2 | $8.55M | Sell |
235,097
-48,452
| -17% | -$1.75M | 0.01% | 851 |
|
|
2025
Q1 | $10.3M | Buy |
283,549
+586
| +0.2% | +$24.4K | 0.01% | 800 |
|
|
2024
Q4 | $11.9M | Buy |
282,963
+7,036
| +3% | +$349K | 0.01% | 773 |
|
|
2024
Q3 | $15.3M | Buy |
275,927
+46,445
| +20% | +$2.37M | 0.02% | 744 |
|
|
2024
Q2 | $9.43M | Buy |
229,482
+9,165
| +4% | +$391K | 0.01% | 826 |
|
|
2024
Q1 | $10.3M | Sell |
220,317
-3,919
| -2% | -$185K | 0.01% | 816 |
|
|
2023
Q4 | $10.7M | Buy |
224,236
+7,000
| +3% | +$271K | 0.01% | 808 |
|
|
2023
Q3 | $7.74M | Buy |
217,236
+1,568
| +0.7% | +$62.1K | 0.01% | 840 |
|
|
2023
Q2 | $9.95M | Sell |
215,668
-735,522
| -77% | -$34.1M | 0.01% | 787 |
|
|
2023
Q1 | $38.1M | Sell |
951,190
-182,222
| -16% | -$7.82M | 0.05% | 499 |
|
|
2022
Q4 | $52.5M | Buy |
1,133,412
+14,017
| +1% | +$551K | 0.06% | 426 |
|
|
2022
Q3 | $46.4M | Buy |
1,119,395
+8,834
| +0.8% | +$454K | 0.06% | 447 |
|
|
2022
Q2 | $66.3M | Buy |
1,110,561
+32,537
| +3% | +$2M | 0.07% | 363 |
|
|
2022
Q1 | $78.3K | Buy |
1,078,024
+153,852
| +17% | +$10.7M | 0.06% | 376 |
|
|
2021
Q4 | $77.7M | Sell |
924,172
-7,097
| -0.8% | -$577K | 0.06% | 375 |
|
|
2021
Q3 | $84M | Sell |
931,269
-2,408
| -0.3% | -$218K | 0.07% | 352 |
|
|
2021
Q2 | $89M | Sell |
933,677
-91,862
| -9% | -$9.57M | 0.07% | 338 |
|
|
2021
Q1 | $117M | Sell |
1,025,539
-141,122
| -12% | -$19.2M | 0.17% | 131 |
|
|
2020
Q4 | $162M | Sell |
1,166,661
-195,692
| -14% | -$23.2M | 0.24% | 90 |
|
|
2020
Q3 | $112M | Sell |
1,362,353
-164,662
| -11% | -$13.6M | 0.19% | 111 |
|
|
2020
Q2 | $119M | Sell |
1,527,015
-95,487
| -6% | -$6.32M | 0.21% | 90 |
|
|
2020
Q1 | $72.1M | Buy |
1,622,502
+208,293
| +15% | +$10.8M | 0.15% | 131 |
|
|
2019
Q4 | $60.4M | Buy |
1,414,209
+178,196
| +14% | +$7.35M | 0.09% | 251 |
|
|
2019
Q3 | $52.9M | Buy |
1,236,013
+438,720
| +55% | +$23.8M | 0.09% | 241 |
|
|
2019
Q2 | $50.6M | Buy |
797,293
+130,561
| +20% | +$8.31M | 0.09% | 261 |
|
|
2019
Q1 | $46.2M | Buy |
666,732
+310,530
| +87% | +$17.7M | 0.08% | 273 |
|
|
2018
Q4 | $15.5M | Buy |
356,202
+93,625
| +36% | +$5.12M | 0.03% | 490 |
|
|
2018
Q3 | $20M | Buy |
+262,577
| New | +$21.4M | 0.03% | 483 |
|
|
2017
Q1 | – | Sell |
-12,900
| Closed | -$907K | – | 1567 |
|
|
2016
Q4 | $907K | Sell |
12,900
-1,800
| -12% | -$128K | ﹤0.01% | 1181 |
|
|
2016
Q3 | $1.04M | Sell |
14,700
-8,700
| -37% | -$555K | ﹤0.01% | 1137 |
|
|
2016
Q2 | $1.14M | Sell |
23,400
-23,233
| -50% | -$1.5M | ﹤0.01% | 1254 |
|
|
2016
Q1 | $2.95M | Sell |
46,633
-9,809
| -17% | -$642K | 0.01% | 846 |
|
|
2015
Q4 | $6.33M | Buy |
56,442
+6,258
| +12% | +$626K | 0.01% | 654 |
|
|
2015
Q3 | $4.83M | Sell |
50,184
-7,153
| -12% | -$819K | 0.01% | 723 |
|
|
2015
Q2 | $5.87M | Buy |
57,337
+28,337
| +98% | +$2.2M | 0.01% | 704 |
|
|
2015
Q1 | $1.8M | Buy |
29,000
+19,138
| +194% | +$1.06M | ﹤0.01% | 1045 |
|
|
2014
Q4 | $433K | Hold |
9,862
| – | – | ﹤0.01% | 1294 |
|
|
2014
Q3 | $558K | Hold |
9,862
| – | – | ﹤0.01% | 1240 |
|
|
2014
Q2 | $443K | Hold |
9,862
| – | – | ﹤0.01% | 1330 |
|
|
2014
Q1 | $482K | Buy |
+9,862
| New | +$508K | ﹤0.01% | 1286 |
|
Other funds holding RARE
RI
BBA
Macquarie Group's RARE Position: Q4 2025 in Review
Macquarie Group sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 200,717 shares — an estimated $6.04M sold.
Macquarie Group first reported a position in RARE in Q1 2014 and held it in 41 quarters. The position peaked at $162M in Q4 2020. 287 funds tracked by Wall St. Rank hold RARE as of Q4 2025.
- Macquarie Group reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
- Macquarie Group sold 200,717 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $6.04M.
- Macquarie Group first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 41 quarters.
- Macquarie Group's Ultragenyx Pharmaceutical position peaked at $162M in Q4 2020.
- 287 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.
Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.